Maia Biotechnology, INC 8-K filings

MAIA Biotechnology shareholders re-elected Class I directors and ratified the appointment of Grant Thornton LLP as auditors.

MAIA Biotechnology, Inc. has announced the termination of its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, effective seven business days after May 14, 2026.

MAIA Biotechnology has activated its first U.S. clinical site for the Phase 2 THIO-101 trial targeting advanced non-small cell lung cancer.

MAIA Biotechnology announced a $33 million capital raise expected to fully fund its Phase 3 trial for ateganosine, a novel telomere-targeting therapy for non-small cell lung cancer.

MAIA Biotechnology announced overall survival exceeding two years for eight non-small cell lung cancer patients in its Phase 2 THIO-101 clinical trial, significantly surpassing expected survival rates.

MAIA Biotechnology, Inc. announced the presentation of positive clinical data for its THIO-101 trial at the European Lung Cancer Congress 2026, highlighting sustained response in NSCLC patients.

MAIA Biotechnology, a clinical-stage biopharmaceutical company, successfully closed an underwritten public offering of 20 million common shares, raising $30 million in gross proceeds.

MAIA Biotechnology announced strong progress in its Phase 3 clinical trial for ateganosine, targeting the $50 billion immunotherapy market for non-small cell lung cancer.

MAIA Biotechnology provides a corporate update on 2025 achievements and outlines key targeted 2026 clinical milestones for its ateganosine cancer treatment program.

MAIA Biotechnology, Inc. has filed presentation materials for its management's use, including at the Biotech Showcase in San Francisco.

MAIA Biotechnology, a clinical-stage biopharmaceutical company, announced a private placement raising approximately $1.51 million to fund its Phase II trial THIO-101 and for working capital.

MAIA Biotechnology has initiated its pivotal Phase 3 THIO-104 trial for ateganosine in advanced non-small cell lung cancer, with leadership demonstrating confidence through significant insider share purchases.

MAIA Biotechnology announces its telomere-targeting agent, ateganosine, aims to address unmet needs in the $50 billion immunotherapy market, particularly for advanced NSCLC patients.

MAIA Biotechnology highlights ongoing momentum for its ateganosine clinical program for non-small cell lung cancer, including patient enrollment and promising survival data.

MAIA Biotechnology announced its CEO presented promising efficacy data for its THIO-101 lung cancer therapy and initiated patient enrollment in Romania for the Phase 2 study.

MAIA Biotechnology, Inc. announced the presentation of two posters detailing its THIO-104 Phase 3 and THIO-101 Phase 2 studies for advanced NSCLC at the SITC 2025 conference.

MAIA Biotechnology announced the presentation of its THIO-101 Phase 2 trial in progress poster and the enrollment of five new patients in Taiwan and Turkey.

MAIA Biotechnology, Inc. announced the presentation of Phase 2 data for its THIO-101 trial in advanced NSCLC at a major cancer conference.

MAIA Biotechnology announced outstanding 30-month patient survival data from its ongoing Phase 2 clinical trial of ateganosine in non-small cell lung cancer.

MAIA Biotechnology, a clinical-stage biopharmaceutical company, announced a private placement of common stock and warrants, raising approximately $736,600 to fund its Phase II THIO-101 trial and for working capital.

MAIA Biotechnology, a clinical-stage biopharmaceutical company, announced a new digital asset treasury strategy, authorizing up to 90% of its liquid assets in top-tier cryptocurrencies.

MAIA Biotechnology, Inc. announced a private placement raising approximately $2.25 million and amended existing warrants, reducing their exercise price to $1.30 per share.

MAIA Biotechnology received a $2.3 million grant from the National Institutes of Health to expand its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer.

MAIA Biotechnology secured approximately $572,654 by inducing accredited investors to exercise existing warrants at a reduced price of $1.30 per share.

MAIA Biotechnology, Inc. announced the posting of an updated business presentation on its website, filed as Exhibit 99.1.

MAIA Biotechnology announced positive efficacy data from its THIO-101 Phase 2 clinical trial for advanced non-small cell lung cancer, showing significantly improved progression-free survival.

MAIA Biotechnology announced positive efficacy data from its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer, showing improved progression-free survival.

MAIA Biotechnology announced the European Patent Office granted a patent for its ateganosine-based analogues, enhancing its intellectual property in telomere-targeting cancer therapy.

MAIA Biotechnology, Inc. announced that its lead drug candidate, Ateganosine, has received FDA Fast Track designation for the treatment of non-small cell lung cancer, potentially accelerating its path to market.

MAIA Biotechnology, Inc. announced the peer-reviewed publication of preclinical data validating its second-generation ateganosine prodrugs, MAIA-2021-20 and MAIA-2022-12, for enhanced anticancer therapy and overcoming drug resistance.